Probiotics in the management of ulcerative colitis

Journal of Clinical Gastroenterology

Volumn 49, Issue , 2015, Pages S50-S55

  Chibbar, Richa ^a   Dieleman, Levinus A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Probiotics; Ulcerative colitis; VSL 3

Indexed keywords

PROBIOTIC AGENT;

ARTICLE; BIFIDOBACTERIUM LONGUM; ESCHERICHIA COLI; HUMAN; LACTOBACILLUS REUTERI; MAINTENANCE THERAPY; MICROFLORA; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; IMMUNOLOGY; INTESTINE FLORA; MICROBIOLOGY; PROCEDURES;

COLITIS, ULCERATIVE; ESCHERICHIA COLI; GASTROINTESTINAL MICROBIOME; HUMANS; PROBIOTICS; REMISSION INDUCTION;

EID: 84944225925     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000368     Document Type: Article

References (30)

1. Bellavia M, Tonasello G, Romeo M, et al. Gut microbiota imbalance and chaperoning system malfunction are central to ulcerative colitis pathogenesis and can be counteracted with specifically designed probiotics: a working hypothesis. Med Microbiol Immunol. 2013;202:393-406.
2. Sartor RB. The intestinal microbiota in inflammatory bowel diseases. Nutrition, gut microbiota and immunity. Therapeutic targets for IBD. Nestle Nutr Inst Workshop Ser. 2014;79:29-39.
3. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489-1499.
4. Ghouri YA, Richards DM, Rahimi EF, et al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473-487.
5. Chen W-X, Ren L-H, Shi R-H. Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. World J Gastroenterol. 2014;20:15657-15663.
6. Lavelle A, Lennon G, O'Sullivan O, et al. Spatial variation of the colonic microbiota in patients with ulcerative colits and control volunteers. Gut. 2015;0:1-9.
7. Fedorak R, Demeria D. Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. Gastroenerol Clin N Am. 2012;41:821-842.
8. Orel R, Trop TK. Intestinal microbiota, probiotics, and prebiotics in inflammatory bowel disease. World J Gastroenterol. 2014;20:11505-11524.
9. Bellavia M, Tomasello G, Romeo M, et al. Gut microbiota imbalance and chaperoning system malfunction are central to ulcerative colitis pathogenesis and can be counteracted with specifically designed probiotics: a working hypothesis. Med Microl Immunol. 2013;202:393-406.
10. Naidoo K, Gordon M, Fagbemi AO, et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2011;12:CD007443.
11. Rembacken BJ, Snelling AM, Hawkey PM, et al. Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet. 1999;354:635-639.
12. Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalamine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Momit. 2004;10:P1126-P1131.
13. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild to moderately active ulcerative colitis. Clin Gastroerntol Hepatol. 2009;7:1202-1209.
14. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probioitc-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539-1546.
15. Miele E, Pascarell F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437-443.
16. Tsuda Y, Yoshimatsu Y, Aoki H, et al. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol. 2007;42:1306-1311.
17. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22:56-63.
18. Ishikawa H, Matsumoto S, Ohashi Y, et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion. 2011;84:128-133.
19. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacerium longum/Syngergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomized controlled pilot trial. Gut. 2005;54:242-249.
20. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:697-698.
21. Olivia S, Di Nardo G, Ferrari F, et al. Randomised controlled trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharamcol Ther. 2012;35:327-334.
22. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853-858.
23. Kruis W, Fric P, Pokrotneiks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalamine. Gut. 2004;53:1617-1623.
24. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-1108.
25. Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1567-1574.
26. Cui HH, Chen CL, Wang JD, et al. Effects on probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004;10:1521-1525.
27. Shanahan F, Guarner F, Von Wright A, et al. A one year, doubleblind, placebo-controlled trial of a Lactobacillus or a Bifidobacterium probiotic for maintenance of a steroid-induced remission or ulcerative colitis. Gastroenterology. 2006;130(suppl 2):A-44.
28. Wildt S, Nordgaard I, Hansen U, et al. A double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subspecies lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis. 2011;5:115-121.
29. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild to moderately active ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo controlled study. Am J Gastroenterol. 2010;105:2218-2227.
30. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebocontrolled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20:1133-1141.